ARS Pharmaceuticals, Inc. — Director's Dealing 2023

Jun 29, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2023-06-27

Reporting Person: Kelly Michael (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-27	Stock Option (right to buy)	$6.50	A	40000	Acquired	2033-06-26	Common Stock (40000)	Direct

Footnotes

F1: The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.